Processing your request...
Dialog Index Results

Your select statement is **'S (DTPA OR ACELLULAR) AND LT(W)K63'** in databases **ALLMEDPH**.

✓ Select All | X Clear Selections | Begin Databases | New Search
Sort Results

File	Database Name	Hits
☐ 9:	Business & Industry(TM)	3
☐ 348:	European Patents Fulltext	1
☐ 349:	WIPO/PCT Patents Fulltext	22
☐ 351:	Derwent World Patents Index®	1
☐ 440:	Current Contents Search®	2
☐ 570:	Gale Group Marketing & Advertising Reference Service®	1
☐ 654:	U.S. Patents Fulltext (1976-present)	15

There are **7** databases matching your statement **'S (DTPA OR ACELLULAR) AND LT(W)K63'**.

Dialog Index Results

Your select statement is **'S (ACELLULAR OR DTPA) AND LT(W)R72'** in databases **ALLMEDPH.**

New Search

Sorry, there were no databases matching your search.

Dialog Index Results

Your select statement is **'S (ACELLULAR OR DTPA) (30N) LT(W)R72'** in databases **ALLMEDPH.**

New Search

Sorry, there were no databases matching your search.

Dialog Index Results

Your select statement is **'S (DTPA OR ACELLULAR)(30N)(LT(W)K63 OR LT(W)R72)'** in databases **ALLMEDPH**.

New Search

Sorry, there were no databases matching your search.

Refine Search

Search Results -

Terms	Documents
(LT adj2 K63 or LT adj2 R72) and (DTPa or acellular)	15

Database: US Pre-Grant Publication Full-Text Database; US Patents Full-Text Database; US OCR Full-Text Database; EPO Abstracts Database; JPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L2

Refine Search | Recall Text | Clear | Interrupt

Search History

DATE: Friday, April 14, 2006 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=OR			
L2	(LT adj2 K63 or LT adj2 R72) and (DTPa or acellular)	15	L2
L1	(LT adj2 K63 or LT adj2 R72) same (DTPa or acellular)	1	L1

END OF SEARCH HISTORY

Hit List

First Hit | Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 11 through 15 of 15 returned.

☐ 11. Document ID: US 20040161420 A1

Using default format because multiple data bases are involved.

L2: Entry 11 of 15 File: PGPB Aug 19, 2004

PGPUB-DOCUMENT-NUMBER: 20040161420
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040161420 A1

TITLE: Plasmid maintenance system for antigen delivery

PUBLICATION-DATE: August 19, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Galen, James E.	Owings Mills	MD	US

US-CL-CURRENT: 424/93.21; 435/320.1, 435/455

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 12. Document ID: US 20020176868 A1

L2: Entry 12 of 15 File: PGPB Nov 28, 2002

PGPUB-DOCUMENT-NUMBER: 20020176868
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020176868 A1

TITLE: Isolation and characterization of the csa operon (ETEC-CS4 pili) and methods of using same

PUBLICATION-DATE: November 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Altboum, Zeev	Ramat Aviv	MD	IL
Levine, Myron M.	Columbia	MD	US
Barry, Eileen M.	Elkridge		US

US-CL-CURRENT: 424/190.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 13. Document ID: US 6977176 B2

L2: Entry 13 of 15 File: USPT Dec 20, 2005

US-PAT-NO: 6977176
DOCUMENT-IDENTIFIER: US 6977176 B2

TITLE: Plasmid maintenance system for antigen delivery

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw D

☐ 14. Document ID: US 6969513 B2

L2: Entry 14 of 15 File: USPT Nov 29, 2005

US-PAT-NO: 6969513
DOCUMENT-IDENTIFIER: US 6969513 B2

TITLE: Plasmid maintenance system for antigen delivery

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw D

☐ 15. Document ID: US 6413768 B1

L2: Entry 15 of 15 File: USPT Jul 2, 2002

US-PAT-NO: 6413768
DOCUMENT-IDENTIFIER: US 6413768 B1

TITLE: Expression plasmids

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw D

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
(LT adj2 K63 or LT adj2 R72) and (DTPa or acellular)	15

Display Format: - Change Format

Previous Page Next Page Go to Doc#

Hit List

First Hit | Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 10 of 15 returned.

☐ 1. Document ID: US 20060051378 A1

Using default format because multiple data bases are involved.

L2: Entry 1 of 15 File: PGPB Mar 9, 2006

PGPUB-DOCUMENT-NUMBER: 20060051378
PGPUB-FILING-TYPE:
DOCUMENT-IDENTIFIER: US 20060051378 A1

TITLE: Mucosal vaccines with chitosan adjuvant and meningococcal antigens

PUBLICATION-DATE: March 9, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Guidice; Giuseppe Del	Siena		IT
Baudner; Barbara	Marburg		DE

US-CL-CURRENT: 424/241.1; 514/55

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 2. Document ID: US 20060034871 A1

L2: Entry 2 of 15 File: PGPB Feb 16, 2006

PGPUB-DOCUMENT-NUMBER: 20060034871
PGPUB-FILING-TYPE:
DOCUMENT-IDENTIFIER: US 20060034871 A1

TITLE: Immunogenic compositions for Chlamydia trachomatis

PUBLICATION-DATE: February 16, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Grandi; Guido	Milano		IT
Ratti; Guilio	Siena		IT
Bonci; Alessandra	Siena		IT
Finco; Oretta	Castelnuovo Berardenga		IT

US-CL-CURRENT: 424/263.1; 435/252.3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 3. Document ID: US 20060030048 A1

L2: Entry 3 of 15 File: PGPB Feb 9, 2006

PGPUB-DOCUMENT-NUMBER: 20060030048
PGPUB-FILING-TYPE:
DOCUMENT-IDENTIFIER: US 20060030048 A1

TITLE: Plasmid maintenance system for antigen delivery

PUBLICATION-DATE: February 9, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Galen; James E.	Owings Mills	MD	US

US-CL-CURRENT: 435/480

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 4. Document ID: US 20060030047 A1

L2: Entry 4 of 15 File: PGPB Feb 9, 2006

PGPUB-DOCUMENT-NUMBER: 20060030047
PGPUB-FILING-TYPE:
DOCUMENT-IDENTIFIER: US 20060030047 A1

TITLE: Plasmid maintenance system for antigen delivery

PUBLICATION-DATE: February 9, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Galen; James E.	Owings Mills	MD	US

US-CL-CURRENT: 435/480

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 5. Document ID: US 20060029616 A1

L2: Entry 5 of 15 File: PGPB Feb 9, 2006

PGPUB-DOCUMENT-NUMBER: 20060029616
PGPUB-FILING-TYPE:
DOCUMENT-IDENTIFIER: US 20060029616 A1

TITLE: Plasmid maintenance system for antigen delivery

PUBLICATION-DATE: February 9, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Galen; James E.	Owings Mills	MD	US

US-CL-CURRENT: 424/200.1; 435/480

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 6. Document ID: US 20060008476 A1

L2: Entry 6 of 15 File: PGPB Jan 12, 2006

PGPUB-DOCUMENT-NUMBER: 20060008476
PGPUB-FILING-TYPE:
DOCUMENT-IDENTIFIER: US 20060008476 A1

TITLE: Adjuvanted antigenic meningococcal compositions

PUBLICATION-DATE: January 12, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Pizza; Mariagrazia	Siena		IT
Guiliani; Marzia Monica	Siena		IT

US-CL-CURRENT: 424/250.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 7. Document ID: US 20050208143 A1

L2: Entry 7 of 15 File: PGPB Sep 22, 2005

PGPUB-DOCUMENT-NUMBER: 20050208143
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050208143 A1

TITLE: Microparticles with adsorbent surfaces, methods of making same, and uses thereof

PUBLICATION-DATE: September 22, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
O' Hagan,. Derek	Berkeley	CA	US
Singh, Manmohan	Hercules	CA	US

Ott, Gary	Oakland	CA	US
Barackman, John	Dublin	CA	US
Kazzaz, Jina	San Rafael	CA	US

US-CL-CURRENT: 424/489; 424/184.1, 514/44

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 8. Document ID: US 20050191319 A1

L2: Entry 8 of 15 File: PGPB Sep 1, 2005

PGPUB-DOCUMENT-NUMBER: 20050191319
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050191319 A1

TITLE: Microparticles with adsorbent surfaces, methods of making same, and uses thereof

PUBLICATION-DATE: September 1, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
O' Hagan, Derek	Berkeley	CA	US
Singh, Manmohan	Hercules	CA	US
Ott, Gary	Oakland	CA	US
Barackman, John	Dublin	CA	US
Kazzaz, Jina	San Rafael	CA	US

US-CL-CURRENT: 424/204.1; 424/234.1, 424/489

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

☐ 9. Document ID: US 20050118275 A1

L2: Entry 9 of 15 File: PGPB Jun 2, 2005

PGPUB-DOCUMENT-NUMBER: 20050118275
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050118275 A1

TITLE: Immunogenic compositions containing microparticles comprising adsorbed toxoid and polysaccharide-containing antigens

PUBLICATION-DATE: June 2, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
O'Hagan, Derek	Berkeley	CA	US

US-CL-CURRENT: 424/490; 424/238.1, 424/239.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | DWIC | Draw D

☐ 10. Document ID: US 20050003539 A1

L2: Entry 10 of 15 File: PGPB Jan 6, 2005

PGPUB-DOCUMENT-NUMBER: 20050003539
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20050003539 A1

TITLE: Plasmid maintenance system for antigen delivery

PUBLICATION-DATE: January 6, 2005

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Galen, James E.	Owings Mills	MD	US

US-CL-CURRENT: 435/455; 435/320.1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | DWIC | Draw D

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
(LT adj2 K63 or LT adj2 R72) and (DTPa or acellular)	15

Display Format: - Change Format

Previous Page Next Page Go to Doc#

Hit List

First Hit | Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 1 of 1 returned.

☐ 1. Document ID: US 20060034871 A1

Using default format because multiple data bases are involved.

L1: Entry 1 of 1 File: PGPB Feb 16, 2006

PGPUB-DOCUMENT-NUMBER: 20060034871
PGPUB-FILING-TYPE:
DOCUMENT-IDENTIFIER: US 20060034871 A1

TITLE: Immunogenic compositions for Chlamydia trachomatis

PUBLICATION-DATE: February 16, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Grandi; Guido	Milano		IT
Ratti; Guilio	Siena		IT
Bonci; Alessandra	Siena		IT
Finco; Oretta	Castelnuovo Berardenga		IT

US-CL-CURRENT: 424/263.1; 435/252.3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw D

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
(LT adj2 K63 or LT adj2 R72) same (DTPa or acellular)	1

Display Format: - Change Format

Previous Page Next Page Go to Doc#

2/3,AB/1 (Item 1 from file: 9)
01914293 Supplier Number: 24668076
What's in the pipeline: Products by company: Chiron
(Lists drug products currently under development by Chiron by product, indication and development status)

R&D Directions What's in the Pipeline Directory , v 5 , n 6 , p 184
June 1999
Document Type: Journal; Directory List **ISSN:** 1079-9397 (United States)
Language: English **Record Type:** Fulltext
Word Count: 199

TEXT:

CHIRON

Product	Indicated for ...	Status
Acellular pertussis vaccine	Pertussis	Phase II clinical trials
Angiozyme	Cancer	Phase I clinical trials
C3/C5 complement inhibitor	Crohn's disease	Preclinical development
CMI-CAB-2	Cardiopulmonary bypass surgery	Preclinical development
CMI-CAB-2	Stroke	Preclinical development
CMI-CAB-2	Respiratory distress syndrome	Preclinical development
Cytomegalo-virus vaccine	Cytomegalovirus	Phase II clinical trials
DepoCyt	Lymphomatous meningitis	Approved
DepoCyt	Neoplastic meningitis	Phase I clinical trials
DepolGF-1	Rheumatoid arthritis	Preclinical development
DTP/ Haemophilus influenzae vaccine	Influenza	Phase I clinical trials
FGF	Coronary artery disease	Phase II clinical trials
Fluad	Influenza	Approved
Haemophilus influenzae vaccine	Haemophilus influenzae	Phase II clinical trials
Haemophilus influenzae vaccine	Influenza	Phase II clinical trials
Helicobacter pylori vaccine	Helicobacter pylori infections	Preclinical development
Hepatitis A vaccine	Hepatitis A	Awaiting approval
Hepatitis B vaccine	Hepatitis B	Phase I clinical trials
Hepatitis C vaccine	Hepatitis C	Phase I clinical trials

HIV infection vaccine	HIV infection	Phase II clinical trials
HIV infection-IT	HIV infection	Phase II clinical trials
HSV-tk	Cancer	Phase I/II clinical trials
HSV-tk	Graft-versus-host disease	Phase I/II clinical trials
HSV-tk	Melanoma	Phase I/II clinical trials
Human papilloma virus vaccine	Papillomavirus	Preclinical development
LT-K63	Influenza	Phase I clinical trials
Meningococcus C vaccine	Meningitis	Phase II clinical trials
Myotrophin	Amyotrophic lateral sclerosis	Awaiting approval
Myotrophin	Multiple sclerosis	Phase I clinical trials
Pertugen	Diphtheria, tetanus, and pertussis	Awaiting approval
Proleukin	Acute myelogenous leukemia	Phase III clinical trials
Proleukin	HIV infection	Phase II clinical trials
Proleukin	Melanoma	Approved
Pylorlmune-G	Helicobacter pylori infections	Phase I/II clinical trials
RabAvert	Rabies	Approved
Theratope	Breast cancer	Phase III clinical trials
Theratope	Colorectal cancer	Phase II clinical trials
Tifacogen	Sepsis	Phase II clinical trials

2/3,AB/2 (Item 2 from file: 9)
01728102 Supplier Number: 24435166
Chiron Corp (49)
(Article profiles Chiron, ranked number 49 among the top 50 drug firms in the world in 1997; net sales were $1,162.1 mil)

PharmaBusiness , n 24 , p 72+
November 1998
Document Type: Journal; Company Overview (United States)
Language: English **Record Type:** Fulltext
Word Count: 3882

ABSTRACT:
Article profiles Chiron Corp (US), which had revenue of $1.16 billion in 1997, up 5.5% from 1996. Net income totaled $71.2 million, up 29.2%. Earnings per share totaled 40 cents, up 29%. The company ranked as number 49 among the top 50 drug firms in the world. The firm is a global concern with an emphasis on vaccines, diagnostics, therapeutics, and technology development. Sales of Chiron products

totaled $839.3 mil in 1997, up 4.3% vs 1996. Chiron Vaccines is a competitor in the global vaccines market, which analysts believe will exceed $17 bil by 2010 vs $4 bil+ now. The article includes much additional information on the company, sales, products, costs, and research spending.

TEXT:

Chiron managers say 1997 was a year characterized both by operational disappointments and delays in product introductions and by some notable successes. By the end of 1997, officials at Chiron received positive regulatory actions on several products, made progress in streamlining the overall asset and cost structure of the company, divested small non-core business components, continued building a strong research and development programme, and increased earnings 29% over 1996, excluding special items.

2/3,AB/3 (Item 3 from file: 9)
01665138 Supplier Number: 24369791
Annual Report: Top 50 Pharmaceutical Companies: 49: Chiron Corp
(Chiron Corp was ranked 49th among the top 50 pharmaceutical companies; product sales totaled $839.3 mil in 1997, up 4.3% vs 1996)

Med Ad News , v 17 , n 9 , p 64+
September 1998
Document Type: Journal; Ranking; Company Overview **ISSN:** 0745-0907 (United States)
Language: English **Record Type:** Fulltext
Word Count: 3875

ABSTRACT:
Chiron Corp (Emeryville, CA) was ranked 49th among the top 50 pharmaceutical companies. The company's revenues totaled $1.16 bil in 1997, a 5.5% gain vs 1996. Net income totaled $71.2 mil, a 29.2% gain vs the previous year. Sales of its products totaled $839.3 mil in 1997, up 4.3% vs 1996. The company's vaccine business, Chiron Vaccines, had sales of $82 mil in 1997. According to analysts, the global vaccines market will exceed $17 bil by 2010, vs more than $4 bil currently. Chiron Therapeutics had sales of $150.6 mil in 1997, up 11% vs 1996. Sales of its Proleukin, a cancer treatment drug, totaled $70.5 mil in 1997, a 15.8% gain vs 1996. The full text tabulates the company's worldwide revenues for 1997 by product, cost and expenses, earnings and balance sheet data. It also lists major health-care products marketed by the firm, products in its pharmaceutical pipeline and courses of action taken by the company in selected months in 1997-98.

TEXT:

Annual Report: Top 50 Pharmaceutical Companies: 49: Chiron Corp

	1997	% Chg. fr.'96
Worldwide revenue		
Pharmaceutical products	$1,162.1	5.5
Net sales	$1,162.1	5.5
Costs and expenses		

Cost of products sold	$354.6	3.7
Marketing, selling, gen. admin.	316.8	2.0
Research and development	376.0	6.7
Other expenses	4.9	(25.2)
Restructuring/reorganization	3.3	100.0
Loss on long-lived assets	31.3	100.0
Total	1,086.9	7.4
Earnings		
Net income	$71.2	29.2
Net earnings per share	0.40	29.0
Balance sheet data		
Working capital	$298.9	33.7
Total assets	1,768.5	4.7
Shareholders' equity	873.9	14.3

Dollars are in millions, except earnings per share data.

2/3,AB/4 (Item 1 from file: 348)
01976936

Rabies vaccine

Title in German: Tollwut-Impfstoff
Title in French: Vaccin antirabique

Patent Assignee: Chiron Behring GmbH & Co., (2301020), Emil-von-Behring-Strasse 76, 35041 Marburg, (DE), (Applicant designated States: all)

Inventor: Banzhoff, Angelika, Dr., Blitzweg 5, 35039 Marburg, (DE)
Malerczyk, Claudius, Dr., Adalbert-Stifter-Weg 8, 35039 Marburg, (DE)

Legal Representative: UEXKULL & STOLBERG (100011), Patentanwalte Beselerstrasse 4, 22607 Hamburg, (DE)

	Patent Number	Kind	Date	
Patent	EP 1593392	A1	051109 (Basic)	
Application	EP 2004023168		040929	
Priority	US 569172		P	040507

Designated States: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IT; LI; LU; MC; NL; PL; PT; RO; SE; SI; SK; TR

International Patent Class: A61K-039/205; A61K-039/42; C07K-016/10

INTERNATIONAL PATENT CLASS (V7): A61K-039/205; A61K-039/42; C07K-016/10

Abstract EP 1593392 A1

The invention provides for an immunogenic rabies vaccine comprising a reduced vaccine dose and

methods of pre- and post-exposure immunization with a reduced dose. The concentration of rabies vaccine antigen per dose is preferably less than 2.5 IU/mL.
Abstract Word Count: 39

Language (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200545	1004
SPEC A	(English)	200545	7593

Total word count	Document A	8597
Total word count	Document B	0
Total word count	Document A + B	8597

2/3,AB/5 (Item 1 from file: 349)
01347786
IMIDAZOQUINOLINE COMPOUNDS
COMPOSES A BASE D'IMIDAZOQUINOLINE

Patent Applicant/Assignee:
CHIRON CORPORATION, 4560 Horton Street, M/S R338, Emeryville, CA 94608-2916 , US, US (Residence), US (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
VALIANTE Nicholas, 32500 Aquado Court, Fremont, CA 94536, US, US (Residence), US (Nationality), (Designated only for: US)
XU Feng, 1025 Arkell Road, Walnut Creek, CA 94598, US, US (Residence), US (Nationality), (Designated only for: US)
LIN Xiaodong, 514N. Civic Drive, Apt. C, Walnut Creek, CA 94596, US, US (Residence), US (Nationality), (Designated only for: US)
CHU Daniel, 3767 Benton Street, Santa Clara, CA 95051, US, US (Residence), US (Nationality), (Designated only for: US)
WANG Xiaojing Michael, 4560 Horton Street, M/S R338, Emeryville, CA 94608-2916, US, US (Residence), US (Nationality), (Designated only for: US)
Legal Representative:
SILVER Joel (agent), 4560 Horton Street, M/S R338, Emeryville, CA 94608-2916, US
Patent and Priority Information (Country, Number, Date):
Patent: WO 200631878 A2 20060323 (WO 0631878)
Application: WO 2005US32721 20050914 (PCT/WO US2005032721)
Priority Application: US 2004609586 20040914; US 2004637107 20041216
Designated States:
(All protection types applied unless otherwise stated - for applications 2004+)
AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ

EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 42560

English Abstract
The invention provides novel compositions comprising imidazoquinoline compounds. Also provided are methods of administering the compositions in an effective amount to enhance the immune response of a subject. Further provided are novel compositions and methods of administering the compositions in combination with (an)other agent(s).

French Abstract
La presente invention a trait a de nouvelles compositions comportant des composes a base d'imidazoquinoline. L'invention a egalement trait a des procedes d'administration des compositions en une quantite efficace pour ameliorer la reponse immunitaire d'un sujet. L'invention a trait en outre a de nouvelles compositions et a des procedes d'administration des compositions en combinaison avec un autre/d'autres agent(s).

2/3,AB/6 (Item 2 from file: 349)
01307080
TRUNCATED HEPATITIS C VIRUS NS5 DOMAIN AND FUSION PROTEINS COMPRISING SAME
DOMAINE NS5 DU VIRUS DE L'HEPATITE C TRONQUE ET PROTEINES HYBRIDES COMPRENANT CE DERNIER

Patent Applicant/Assignee:
CHIRON CORPORATION, Intellectual Property - R440, P. O. Box 8097, Emeryville, CA 94662, US, US (Residence), US (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
HOUGHTON Michael, c/o Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608, US, US (Residence), GB (Nationality), (Designated only for: US)
Legal Representative:
MORAN Michael J (agent), Chiron Corporation, Intellectual Property - R440, P. O. Box 8097, Emeryville, CA 94662, US,
Patent and Priority Information (Country, Number, Date):
Patent: WO 2005113837 A2 20051201 (WO 05113837)
Application: WO 2005US17377 20050517 (PCT/WO US05017377)
Priority Application: US 2004571985 20040517
Designated States:
(All protection types applied unless otherwise stated - for applications 2004+)

AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 23412

English Abstract

The invention provides truncated HCV NS5 polypeptides and fusion proteins comprising the truncated NS5 polypeptides, fused to at least one other HCV epitope derived from another region of the HCV polyprotein. The fusions can be used in methods of stimulating an immune response to HCV, for example a cellular immune response to HCV, such as activating hepatitis C virus (HCV)?specific T cells, including CD4"sup"+ and CD8"sup"+ T cells. The method can be used in model systems to develop HCV?specific immunogenic compositions, as well as to immunize a mammal against HCV.

French Abstract

L'invention concerne des polypeptides NS5 du VHC tronques et des proteines hybrides comprenant ces polypeptides NS5 tronques, fusionnes a au moins un autre epitope de VHC derive d'une autre region de la polyproteine de VHC. Ces proteines hybrides peuvent etre utilisees dans des methodes visant a stimuler une reponse immunitaire au VHC, telle qu'une reponse immunitaire cellulaire au VHC, pour activer des lymphocytes T specifiques du virus de l'hepatite C, y compris des lymphocytes CD4"sup"+ et CD8"sup"+. Cette methode peut egalement etre utilisee dans des systemes modeles destines a la mise au point de compositions immunogenes specifiques du VHC, ainsi que pour immuniser un mammifere contre le VHC.

2/3,AB/7 (Item 3 from file: 349)
01302673
INFLUENZA VIRUS VACCINES
VACCINS ANTIGRIPPAUX

Patent Applicant/Assignee:
CHIRON CORPORATION, 4560 Horton Street, Emeryville, CA 94608-2916, US, US (Residence), US (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
PODDA Audino, Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097, US, IT (Residence), IT (Nationality), (Designated only for: US)
POPOVA Olga, Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097, US, IT (Residence), IT (Nationality), (Designated only for: US)
PICCENETTI Francesca, Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097, US, IT (Residence), IT (Nationality), (Designated only for: US)
Legal Representative:

HALE Rebecca M (et al) (agent), Chiron Corporation, Intellectual Property R338, P. O. Box 8097, Emeryville, CA 94662-8097, US,
Patent and Priority Information (Country, Number, Date):
Patent: WO 2005107797 A1 20051117 (WO 05107797)
Application: WO 2005US8005 20050309 (PCT/WO US05008005)
Priority Application: US 2004551897 20040309; US 2004556534 20040325
Designated States:
(All protection types applied unless otherwise stated - for applications 2004+)
AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 8215

English Abstract
The invention provides a vaccine for protecting a human patient against infection by a human influenza virus strain, wherein the vaccine comprises an antigen from an avian influenza virus strain that can cause highly pathogenic avian influenza. The antigen can invoke an antibody response in the patient that is capable of neutralising said human influenza virus strain. Whereas the prior art used known non-pathogenic avian strains to generate antibodies in humans against known pathogenic avian strains, the invention uses known pathogenic avian strains to protect against emerging pathogenic human strains. Furthermore, whereas the prior art focused on achieving a close antigenic match between the vaccine strain and the target strain, the invention selects vaccine strains based on their pathogenicity, regardless of any perceived close antigenic relationship to the target strain. As the invention does not require detailed knowledge of an emerging strain, a vaccine can be provided further in advance to reduce the risk and potential effects of a human pandemic outbreak.

French Abstract
L'invention concerne un vaccin destine a proteger un patient humain contre une infection par une souche de virus de la grippe humaine, le vaccin comprenant une antigene derive d'une souche de virus de la grippe aviaire pouvant entrainer une grippe aviaire hautement pathogene. L'antigene peut impliquer une reponse d'anticorps chez le patient qui est capable de neutraliser ladite souche de virus de la grippe humaine. Alors que dans l'etat anterieur de la technique etaient utilisees des souches aviaires non pathogenes connues pour generer, chez les humains, des anticorps diriges contre des souches aviaires pathogene connues, l'invention fait appel a des souches aviaires pathogenes connues pour la protection contre des souches humaines pathogenes emergeantes. En outre, alors que l'etat anterieur de la technique etait centre sur l'obtention d'une correspondance antigenique etroite entre la souche de vaccin et la souche cible, l'invention fait appel a la selection de souches de vaccins en fonction de leur pathogenicite, independamment de toute relation antigenique etroite percue avec la souche cible. Etant donne que l'invention ne necessite pas de connaissance detaillee d'une souche emergeante, un vaccin peut etre fourni bien a l'avance pour reduire le risque et les effets eventuels d'une pandemie humaine.

2/3,AB/8 (Item 4 from file: 349)
01299900

COMBINED MENINGOCOCCAL CONJUGATES WITH COMMON CARRIER PROTEIN
CONJUGUES MENINGOCOCCIQUES COMBINES PRESENTANT UNE PROTEINE PORTEUSE COMMUNE

Patent Applicant/Assignee:
CHIRON SRL, Via Fiorentina, 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
COSTANTINO Paulo, Chiron Srl, Via Fiorentina 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (Designated only for: US)
Legal Representative:
MARSHALL Cameron John et al (agent), Carpmaels & Ransford, 43-45 Bloomsbury Square, London WC1A 2RA, GB
Patent and Priority Information (Country, Number, Date):
Patent: WO 2005105141 A2-A3 20051110 (WO 05105141)
Application: WO 2005IB1536 20050429 (PCT/WO IB2005001536)
Priority Application: GB 200497457 20040430
Designated States:
(All protection types applied unless otherwise stated - for applications 2004+)
AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 13675

English Abstract
Carrier-induced epitopic suppression is of particular concern where multiple conjugates with the same carrier protein are administered simultaneously. To avoid the suppression, the invention minimises the amount of unconjugated carrier protein in a vaccine. The invention provides a composition for immunising a patient against a disease caused by Neisseria meningitidis, wherein (1) the composition comprises conjugates for at least two of the four meningococcal serogroups A, C, W135 and Y, where at least two of the conjugates have a common carrier protein; and (2) the composition includes the common carrier in an unconjugated form at less than 10 mug/ml.

French Abstract
La suppression epitopique induite par un porteur pose particulierement probleme, lorsque plusieurs conjugues presentant la meme proteine porteuse sont administres simultanement. Pour eviter cette suppression, l'invention vise a reduire la quantite de proteines porteuses non conjuguees dans un vaccin. L'invention concerne une composition pour immuniser un patient contre une maladie provoquee par Neisseria meningitidis. (1) Cette composition comprend des conjugues pour au moins deux des quatre serogroupes meningococciques A, C, W135 et Y, au moins deux de ces conjugues presentant une proteine porteuse commune; et (2) la composition comprend le porteur commun sous une forme

non conjuguee a moins de 10 ?g/ml.

2/3,AB/9 (Item 5 from file: 349)
01297200

IMMUNISING AGAINST MENINGOCOCCAL SEROGROUP Y USING PROTEINS
IMMUNISATION CONTRE DES SEROGROUPES MENINGOCOCCIQUES PAR DES PROTEINES

Patent Applicant/Assignee:
CHIRON SRL, Via Fiorentina, 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
CONTORNI Mario, Chiron Srl, Via Fiorentina, 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (Designated only for: US)
GIULIANI Marzia, Chiron Srl, Via Fiorentina, 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (Designated only for: US)
PIZZA Mariagrazia, Chiron Srl, Via Fiorentina, 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (Designated only for: US)
Legal Representative:
MARSHALL Cameron John et al (agent), Carpmaels & Ransford, 43-45 Bloomsbury Square, London WC1A 2RA, GB
Patent and Priority Information (Country, Number, Date):
Patent: WO 2005102384 A2-A3 20051103 (WO 05102384)
Application: WO 2005IB1279 20050422 (PCT/WO IB2005001279)
Priority Application: GB 200489777 20040422
Designated States:
(All protection types applied unless otherwise stated - for applications 2004+)
AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 15103

English Abstract
The established dogma for meningococcus is thus that immunisation against serogroups A, C, W135 and Y shall be based on the four different capsular saccharides, and that immunisation against serogroup B shall not be based on the capsular saccharide. In contrast, the invention uses polypeptide antigens and/or OMVs to immunise against serogroups A, C, W135 and Y (and against serogroup Y in particular). Serogroup B polypeptides can achieve this protection, thus permitting a single polypeptide-based vaccine to be used for protecting against all of serogroups A, B, C, W 135 and Y.

French Abstract
Selon la theorie etablie concernant le meningocoque, l'immunisation contre les serogroupes A, C, W135 et Y doit s'appuyer sur les quatre differents saccharides capsulaires, et l'immunisation contre le serogroupe B ne doit pas s'appuyer sur le saccharide capsulaire. En revanche, l'invention concerne l'utilisation d'antigenes polypeptidiques et/ou des OMV par rapport a l'immunisation contre les serogroupes A, C, W135 et Y (notamment contre le serogroupe Y). Les polypeptides du serogroupe B peuvent assurer cette protection, ce qui permet d'utiliser un vaccin a base de polypeptides simples pour la protection contre tous les serogroupes A, C, W135 et Y.

2/3,AB/10 (Item 6 from file: 349)
01279403
IMMUNOGENIC COMPOSITIONS FOR CHLAMYDIA PNEUNOMIAE
COMPOSITIONS IMMUNOGENES POUR <I>CHLAMYDIA PNEUNOMIAE</I>

Patent Applicant/Assignee:
CHIRON CORPORATION, 4560 Horton Street, Emeryville, CA 94608-2916, US, US (Residence), US (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
GRANDI Guido, c/o 4560 Horton Street, Emeryville, CA 94608, US, IT (Residence), IT (Nationality), (Designated only for: US)
GIULIO Ratti, C/o 4560 Horton Street, Emeryville, CA 94608, US, IT (Residence), IT (Nationality), (Designated only for: US)
Legal Representative:
HALE Rebecca M (agent), Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608-2916, US,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200584306 A2 20050915 (WO 0584306)
Application: WO 2005US6588 20050302 (PCT/WO US05006588)
Priority Application: US 2004549832 20040302; US 2005643110 20050112; US 2005644552 20050119
Designated States:
(All protection types applied unless otherwise stated - for applications 2004+)
AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 68781

English Abstract
The invention relates to polypeptides for use as an autotransporter antigen. The invention further

relates to methods and uses of a polypeptide for an autotransporter function in preparation of a medicament for the prevention or treatment of a Chlamydia pneumoniae infection or for the preparation of an assay for the diagnosis of a Chlamydia pneumoniae infection in an individual. Also, a method is provided for raising an immune response in an individual by administering to the individual a polypeptide for use as an autotransporter antigen.

French Abstract

La presente invention a trait a des polypeptides destines a etre utilises comme un antigene transporteur autonome. L'invention a egalement trait a des procedes et des utilisations d'un polypeptide pour une fonction de transporteur autonome dans la preparation d'un medicament pour la prevention ou le traitement d'une infection de Chlamydia pneumoniae ou pour la preparation d'un dosage pour le diagnostic d'une infection de Chlamydia pneumoniae chez un sujet. L'invention a trait en outre a un procede pour provoquer une reponse immunitaire chez un sujet par l'administration au sujet d'un polypeptide destine a etre utilise comme un antigene transporteur autonome.

2/3,AB/11 (Item 7 from file: 349)
01235956

STABILISED COMPOSITIONS
COMPOSITIONS STABILISEES

Patent Applicant/Assignee:
CHIRON CORPORATION, 4560 Horton Street, Emeryville, CA 94608, US, US (Residence), US (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
MAGAGNOLI Claudia, Via Fiorentina 1, I-53100 Siena, IT, IT (Residence), IT (Nationality)
MORANDI Maurizio, Via Fiorentina 1, I-53100 Siena, IT, IT (Residence), IT (Nationality)
Legal Representative:
HALE Rebecca (et al) (agent), Chiron Corporation, Intellectual Property - R440, P. O. Box 8097, Emeryville, CA 94662-8097, US,

Patent and Priority Information (Country, Number, Date):
Patent: WO 200542016 A2-A3 20050512 (WO 0542016)
Application: WO 2004US35039 20041022 (PCT/WO US04035039)
Priority Application: US 2003514307 20031023; US 2004561999 20040413
Designated States:
(All protection types applied unless otherwise stated - for applications 2004+)
AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 34139

English Abstract
This invention relates to the stabilization of a bacterial ADP-ribosylating exotoxin class protein (bARE), a method for analysing a bARE class protein, a method for the stabilization of the bARE class bacterial protein, compositions comprising a stabilized bARE protein, compositions comprising a substantially integral bARE class protein and immunogenic composition formulations incorporating same.

French Abstract
L'invention concerne la stabilisation d'une proteine de classe exotoxine ADP-ribosylante bacterienne, un procede pour analyser une proteine de classe exotoxine ADP-ribosylante bacterienne, un procede pour stabiliser la proteine de classe exotoxine ADP-ribosylante bacterienne, des compositions comprenant une proteine de classe exotoxine ADP-ribosylante bacterienne stabilisee, des compositions comprenant une proteine de classe exotoxine ADP-ribosylante bacterienne pratiquement integrale, ainsi que des formulations de compositions immunogenes renfermant cette derniere.

2/3,AB/12 (Item 8 from file: 349)
01227118
LIQUID VACCINES FOR MULTIPLE MENINGOCOCCAL SEROGROUPS
VACCINS LIQUIDES CONTRE DE MULTIPLES SEROGROUPES MENINGOCOCCIQUES

Patent Applicant/Assignee:
CHIRON SRL, Via Fiorentina 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
CONTORNI Mario, Chiron SRL, Via Fiorentina 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (Designated only for: US)
Legal Representative:
MARSHALL Cameron John et al (agent), Carpmaels & Ransford, 43-45 Bloomsbury Square, London WC1A 2RA, GB
Patent and Priority Information (Country, Number, Date):
Patent: WO 200532583 A2-A3 20050414 (WO 0532583)
Application: WO 2004IB3373 20041004 (PCT/WO IB2004003373)
Priority Application: GB 2003231024 20031002; GB 2004120523 20040528
Designated States:
(All protection types applied unless otherwise stated - for applications 2004+)
AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English

Fulltext Word Count: 20676

English Abstract

Conjugated capsular saccharides from meningococcal serogroups C, W135 and Y are safe and immunogenic in humans when combined in a single dose. This effect is retained when a conjugated capsular saccharide from serogroup A is added. These conjugated antigens can be stably combined in a single aqueous dose without the need for lyophilisation. Broad protection against serogroup B infection can be achieved by using a small number of defined polypeptide antigens. These polypeptide antigens can be combined with the saccharide antigens without loss of protective efficacy for any of the five serogroups. Efficacy if retained even if a Hib conjugate is added. The efficacy of a serogroup W135 conjugate is enhanced by addition of protein antigens derived from a serogroup B strain. Addition of a Hib conjugate to meningococcal conjugates enhances the overall activity against meningococcus serogroup W135.

French Abstract

Des saccharides capsulaires conjugues issus des serogroupes meningococciques C, W135 et Y sont inoffensifs et immunogenes chez l'homme lorsqu'ils sont associes dans une dose unique. Cet effet est conserve lorsqu'un saccharide capsulaire conjugue issu du serogroupe A est ajoute. Ces antigenes conjugues peuvent etre associes de maniere stable dans une dose aqueuse unique sans recours a la lyophilisation. L'emploi d'un petit nombre d'antigenes polypeptidiques definis permet d'obtenir une couverture a large spectre contre l'infection par le serogroupe B. Ces antigenes polypeptidiques peuvent etre associes aux antigenes saccharidiques sans perte de l'efficacite de la couverture contre n'importe lequel des cinq serogroupes. Cette efficacite est conservee meme si un conjugue de Hib est ajoute. L'efficacite d'un conjugue du serogroupe W135 est accrue par l'adjonction d'antigenes proteiques derives d'une souche du serogroupe B. L'adjonction d'un conjugue de Hib aux conjugues meningococciques renforce l'activite globale contre le serogroupe meningococcique W135.

2/3,AB/13 (Item 9 from file: 349)
01215677

IMMUNOGENIC COMPOSITIONS BASED ON MICROPARTICLES COMPRISING ADSORBED TOXOID AND A POLYSACCHARIDE-CONTAINING ANTIGEN
COMPOSITIONS IMMUNOGENES BASEES SUR DES MICROPARTICULES COMPRENANT DES ANTIGENES CONTENANT DE L'ANATOXINE ADSORBEE ET DES POLYSACCHARIDES

Patent Applicant/Assignee:
CHIRON CORPORATION, 4560 Horton Street, Emeryville, CA 94608, US, US (Residence), US (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
O'HAGAN Derek, 2372 Woolsey Street, Berkeley, CA 94705, US, US (Residence), GB (Nationality), (Designated only for: US)
SINGH Manmohan, 127 Pepperwood Street, Hercules, CA 94547, US, US (Residence), IN (Nationality) , (Designated only for: US)
KAZZAZ Jina, 1 Canada Court, San Rafael, CA 94903, US, US (Residence), US (Nationality), (Designated only for: US)
Patent and Priority Information (Country, Number, Date):
Patent: WO 200520964 A1 20050310 (WO 0520964)

Application: WO 2004US17125 20040602 (PCT/WO US04017125)
Priority Application: US 2003475010 20030602; US 2003513074 20031021
Designated States:
(All protection types applied unless otherwise stated - for applications 2004+)
AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 17446

English Abstract
Immunogenic compositions comprising microparticles with adsorbed toxoid antigen and/or polysaccharide-containing antigen are disclosed. The immunogenic microparticle compositions comprising (a) polymer microparticles comprising a biodegradable polymer; (b) an antigen adsorbed to the microparticles selected from (i) a toxoid antigen, such as a tetanus toxoid, a diphtheria toxoid, or a combination thereof, and/or (ii) a polysaccharide containing antigen, such as a Hib polysaccharide antigen, a Hib conjugate antigen comprising polysaccharide and polypeptide regions, a meningococcal polysaccharide antigen, a meningococcal conjugate antigen comprising polysaccharide and polypeptide regions, a pneumococcal polysaccharide antigen, and a pneumococcal conjugate antigen comprising poysaccharide and polypeptide regions or a combination thereof; and (c) a pharmaceutically acceptable excipient. The biodegradable polymer can be, for example, a polymer selected from a poly(alpha-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and a polycyanoacrylate. Also disclosed are methods of immunization against infection by a pathogenic organisms and methods stimulating immune responses, which comprise administering such compositions to host animals. Methods of producing such microparticle compositions are also disclosed which comprise forming a water-in-oil-in-water emulsion that contains water, organic solvent and biodegradable polymer, followed by removal of the organic solvent from the emulsion to form microparticles, after which toxoid and/or polysaccharide containing antigens are adsorbed on the microparticles.

French Abstract
L'invention concerne des compositions immunogenes contenant des microparticules a antigenes contenant de l'anatoxine adsorbee et/ou des polysaccharides. Les compositions de microparticules immunogenes contiennent (a) des microparticules polymeres contenant un polymere biodegradable; (b) un antigene adsorbe par les microparticules selectionnees parmi (i) un antigene d'anatoxine, notamment une anatoxine tetanique, une anatoxine diphterique, ou une combinaison de ceux-ci et/ou (ii) un antigene contenant des polysaccharides, notamment un antigene a polysaccharide Hib, un antigene Hib conjugue contenant des zones polypeptides et polysaccharides, un antigene a polysaccharides meningococciques, un antigene meningococcique conjugue contenant des zones polypeptides et polysaccharides, un antigene a polysaccharides pneumococciques, et un antigene pneumococcique conjugue comprenant des zones polypeptides et polysaccharides ou une combinaison de ceux-ci; et (c) un excipient acceptable sur le plan pharmaceutique. Le polymere biodegradable peut etre, par exemple, un polymere choisi parmi un acide polyhydroxyle, un acide polyhydroxy butyrique, un polycaprolactone, un polyorthoester, un polyanhydride, et un polycyanoacrylate. L'invention concerne

egalement des procedes d'immunisation contre les infections par des organismes pathogenes et des procedes de stimulation des reponses immunitaires, qui consistent a administrer ces compositions a des animaux hotes. L'invention concerne enfin des procedes de production de ces compositions a microparticules par formation d'une emulsion eau dans huile dans eau contenant de l'eau, du solvant organique et un polymere biodegradable, puis par elimination du solvant organique de l'emulsion afin de former les microparticules, apres quoi les antigenes contenant des polysaccharides et/ou de l'anatoxine sont adsorbees sur les microparticules.

2/3,AB/14 (Item 10 from file: 349)
01197398

IMMUNOGENIC COMPOSITIONS FOR CHLAMYDIA TRACHOMATIS
COMPOSITIONS IMMUNOGENES POUR LUTTER CONTRE <I>CHLAMYDIA TRACHOMATIS</I>

Patent Applicant/Assignee:
CHIRON CORPORATION, 4560 Horton Street, Emeryville, CA 94608-2916, US, US (Residence), US (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
GRANDI Guido, c/o Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097, US, IT (Residence), IT (Nationality), (Designated only for: US)
FINCO Oretta, c/o Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097, US, IT (Residence), IT (Nationality), (Designated only for: US)
RATTI Giulio, c/o Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097, US, IT (Residence), IT (Nationality), (Designated only for: US)
BONCI Alessandro, c/o Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097, US, IT (Residence), IT (Nationality), (Designated only for: US)
Legal Representative:
HALE Rebecca M (et al) (agent), Chiron Corporation, Intellectual Property R338, P. O. Box 8097, Emeryville, CA 94662-8097, US,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200502619 A2-A3 20050113 (WO 0502619)
Application: WO 2004US20491 20040625 (PCT/WO US04020491)
Priority Application: GB 200315020 20030626; US 2003497649 20030825; GB 20042236 20040202; US 2004576375 20040601
Designated States:
(All protection types applied unless otherwise stated - for applications 2004+)
AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English

Fulltext Word Count: 12573

English Abstract

The invention relates to compositions comprising combinations of Chlamydia trachomatis antigens and their use in vaccines. Specific combinations may be selected from a first antigen group of PepA, LcrE, ArtJ, DnaK, and CT398, and a second antigen group of PepA, LcrE, ArtJ, DnaK, CT398, OmpH-like, L7/L12, OmcA, AtoS, CT547, Eno, HtrA and MurG. The invention further relates to the use of combinations of adjuvants for use with antigens associated with a sexually transmissible disease, such as Chlamydia trachomatis antigens. Preferred adjuvant combinations include mineral salts, such as aluminium salts and oligonucleotides comprising a CpG motif.

French Abstract

L'invention concerne des compositions comprenant des combinaisons d'antigenes de Chlamydia trachomatis et leur utilisation dans des vaccins. Des combinaisons specifiques peuvent etre selectionnees a partir d'un premier groupe d'antigenes, constitue de PepA, LcrE, ArtJ, DnaK et CT398, et d'un second groupe d'antigenes, constitue de PepA, LcrE, ArtJ, DnaK, CT398, proteines analogues a celles de la membrane exterieure H (OmpH-like), L7/L12, OmcA, AtoS, CT547, Eno, HtrA et MurG. L'invention concerne egalement l'utilisation de combinaisons d'adjuvants destinees a etre utilisees avec des antigenes associes a une maladie sexuellement transmissible, tels que les antigenes de Chlamydia trachomatis. Des combinaisons d'adjuvants preferees comprennent des sels mineraux, tels que des sels d'aluminium, et des oligonucleotides comprenant un motif CpG.

2/3,AB/15 (Item 11 from file: 349)
01186531

PREVENTION OF PULMONARY IMMUNOPATHOLOGY USING MUTANT BACTERIAL TOXINS
PREVENTION D'UNE IMMUNOPATHOLOGIE PULMONAIRE A L'AIDE DE TOXINES BACTERIENNES MUTANTES

Patent Applicant/Assignee:
IMPERIAL COLLEGE INNOVATIONS LIMITED, Sherfield Building, Imperial College, London SW7 2AZ, GB, GB (Residence), GB (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
HUSSELL Tracy, Centre For Molecular Microbiology And Infection, Department of Biological Sciences, Imperial College London, London SW7 2AZ, GB, GB (Residence), GB (Nationality), (Designated only for: US)
Legal Representative:
MARSHALL Cameron John (et al) (agent), Carpmaels & Ransford, 43-45 Bloomsbury Square, London WC1A 2RA, GB,
Patent and Priority Information (Country, Number, Date):
Patent: WO 2004108154 A1 20041216 (WO 04108154)
Application: WO 2004GB2333 20040601 (PCT/WO GB04002333)
Priority Application: GB 200313242 20030609
Designated States:
(All protection types applied unless otherwise stated - for applications 2004+)
AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT

LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 9944

English Abstract
The LT-K63 mutant of E.coli heat-labile toxin has been found to lead to protection against the pathological consequences of infection with unrelated organisms, particularly respiratory pathogens, including viruses. Alteration of the lung microenvironment by the protein may provide generic protection against a number of infectious diseases. The invention provides a method for protecting a patient against immunopathology, comprising the step of administering a detoxified mutant of an ADP-ribosyltransferase to the patient.

French Abstract
L'invention concerne un mutant LT-K63 de la toxine labile a la chaleur de E.coli garantissant une protection contre les consequences pathologiques d'une infection due a des organismes non associes, en particulier des agents pathogenes respiratoires, y compris des virus. L'alteration du micro-environnement pulmonaire par la proteine garantit une protection generique contre un certain nombre de maladies infectieuses. L'invention concerne egalement une methode visant a proteger un patient contre une immunopathologie, et consistant a administrer au patient un mutant detoxifie d'une ADP-ribosyltransferase.

2/3,AB/16 (Item 12 from file: 349)
01171672
THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS
LE CORONAVIRUS DU SYNDROME RESPIRATOIRE AIGU GRAVE

Patent Applicant/Assignee:
CHIRON CORPORATION, 4560 Horton Street, Emeryville, CA 94608-2916, US, US (Residence), US (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
RAPPUOLI Rino, c/o Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097, US, IT (Residence), IT (Nationality), (Designated only for: US)
MASIGNANI Vega, c/o Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097, US, IT (Residence), IT (Nationality), (Designated only for: US)
STADLER Konrad, c/o Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097, US, DE (Residence), DE (Nationality), (Designated only for: US)
GREGERSEN Jens-Peter, c/o Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097, US, DE (Residence), DE (Nationality), (Designated only for: US)
CHIEN David, c/o Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097, US , US (Residence), US (Nationality), (Designated only for: US)

HAN Jang, c/o Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097, US, US (Residence), US (Nationality), (Designated only for: US)
POLO John, c/o Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097, US, US (Residence), US (Nationality), (Designated only for: US)
WEINER Amy, c/o Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097, US, US (Residence), US (Nationality), (Designated only for: US)
HOUGHTON Michael, c/o Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097, US, US (Residence), GB (Nationality), (Designated only for: US)
SONG Hyun Chul, c/o Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097, US, US (Residence), KR (Nationality), (Designated only for: US)
SEO Mi Young, c/o Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097, US, US (Residence), KR (Nationality), (Designated only for: US)
DONNELLY John J, c/o Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097, US, US (Residence), US (Nationality), (Designated only for: US)
KLENK Hans Dieter, c/o Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097, US, DE (Residence), DE (Nationality), (Designated only for: US)
VALIANTE Nicholas, c/o Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097, US, US (Residence), US (Nationality), (Designated only for: US)
Legal Representative:
HALE Rebecca M (et al) (agent), Chiron Corporation, Intellectual Property R338, P.O. Box 8097, Emeryville, CA 94662-8097, US,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200492360 A2-A3 20041028 (WO 0492360)
Application: WO 2004US11710 20040409 (PCT/WO US04011710)
Priority Application: US 2003462218 20030410; US 2003462465 20030411; US 2003462418 20030412; US 2003462748 20030413; US 2003463109 20030414; US 2003463460 20030415; US 2003463668 20030416; US 2003463983 20030417; US 2003463971 20030418; US 2003464899 20030422; US 2003464838 20030422; US 2003465273 20030423; US 2003465535 20030424; US 2003468312 20030505; US 2003473144 20030522; US 2003495024 20030814; US 2003505652 20030923; US 2003510781 20031011; US 2003529464 20031211; US 2004536177 20040112; US 2004560757 20040407
Designated States:
(All protection types applied unless otherwise stated - for applications 2004+)
AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 257775

English Abstract
An outbreak of a virulent respiratory virus, now known as Severe Acute Respiratory Syndrome (SARS), was identified in Hong Kong, China and a growing number of countries around the world in 2003. The invention relates to nucleic acids and proteins from the SARS coronavirus. These nucleic acids and proteins can be used in the preparation and manufacture of vaccine formulations, diagnostic

reagents, kits, etc. The invention also provides methods for treating SARS by administering small molecule antiviral compounds, as well as methods of identifying potent small molecules for the treatment of SARS.

French Abstract

On a identifie une epidemie provoquee par un virus respiratoire, connu maintenant comme syndrome respiratoire aigu grave, a Hong Kong, en Chine et dans un nombre croissant de pays a travers le monde en 2003. L'invention a trait a des acides nucleiques et des proteines a partir du coronavirus du syndrome respiratoire aigu grave. Ces acides nucleiques et ces proteines peuvent etre utilises dans la preparation et la fabrication de formulations vaccinales, de reactifs de diagnostic, de trousses, et analogues. L'invention a egalement trait a des procedes pour le traitement du syndrome respiratoire aigu grave par l'administration de composes antiviraux de petites molecules, ainsi qu'a des procedes d'identification de petites molecules efficaces pour le traitement du syndrome respiratoire aigu grave.

2/3,AB/17 (Item 13 from file: 349)
01145514

MUCOSAL MENINGOCOCCAL VACCINES
VACCINS CONTRE LE MENINGOCOQUE ADMINISTRES PAR LA MUQUEUSE

Patent Applicant/Assignee:
CHIRON SRL, Via Fiorentina 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (For all designated states except: US)
UNIVERSITEIT LEIDEN, Leiden/Amsterdam Center for Drug Research, Einsteinweg 55, NL-2333 CC Leiden, NL, NL (Residence), NL (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
DEL GIUDICE Giuseppe, Chiron Srl, Via Florentina, 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (Designated only for: US)
BAUDNER Barbara, Chiron Srl, Via Fiorentina, 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (Designated only for: US)
Legal Representative:
MARSHALL Cameron John (agent), Carpmaels & Ransford, 43-45 Bloomsbury Square, London WC1A 2RA, GB,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200467033 A1 20040812 (WO 0467033)
Application: WO 2004IB673 20040130 (PCT/WO IB04000673)
Priority Application: GB 20032218 20030130; WO 2003IB2382 20030514
Designated States:
(All protection types applied unless otherwise stated - for applications 2004+)
AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English
Filing Language: English
Fulltext Word Count: 12316

English Abstract
The invention provides immunogenic compositions for mucosal delivery comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of N.meningitidis. It is preferred that the capsular saccharides in the compositions of the invention are conjugated to carrier protein(s) and/or are oligosaccharides. Conjugated oligosaccharide antigens are particularly preferred. The invention also provides immunogenic compositions comprising (a) a capsular saccharide antigen from serogroup C of N.meningitidis, and (b) a chitosan adjuvant. The composition preferably comprises (c) one or more further antigens and/or (d) one or more further adjuvants. The compositions are particularly suitable for mucosal delivery, including intranasal delivery. The use of chitosan and/or detoxified ADP-ribosylating toxin adjuvants enhances anti-meningococcal mucosal immune responses and can shift the Thl/Th2 bias of the responses.

French Abstract
L'invention concerne des compositions immunogenes en vue d'une administration muqueuse comprenant des sacharrides capsulaires provenant au moins de deux des serogroupes A, C, W135 et Y de N.meningitidis. Les sacharrides capsulaires contenus dans les compositions de cette invention sont, de preference, conjugues a une (des) proteine(s) porteuse(s) et/ou sont des oligosaccharides. On retient de preference des antigenes d'oligosaccharides conjugues. L'invention concerne egalement des compositions immunogenes comprenant (a) un antigene de saccharide capsulaire provenant du serogroupe C de N.meningitidis, et (b) un adjuvant de chitosane. La composition renferme de preference (c) un ou plusieurs antigenes et/ou des un ou plusieurs adjuvants. Les compositions se pretent particulierement a une administration muqueuse, y compris l'administration intranasale. L'utilisation de chitosane et/ou d'adjuvants de toxines detoxifies de ribosylation ADP ameliore les reponses immunes muqueuses anti-meningocoque et permet la deformation des reponse Th1/Th2.

2/3,AB/18 (Item 14 from file: 349)
01121061
GROUP B STREPTOCOCCUS VACCINE
VACCIN CONTRE LES STREPTOCOQUES DU GROUPE B

Patent Applicant/Assignee:
CHIRON CORPORATION, 4560 Horton Street, Emeryville, CA 94608-2916, US, US (Residence), US (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
RAPPUOLI Rino, Chiron Corporation, P.O. Box 8097, Emeryville, CA 94662-8097 , US, IT (Residence), IT (Nationality), (Designated only for: US)
Legal Representative:
HALE Rebecca M (et al) (agent), Chiron Corporation, Intellectual Property-R338, P.O. Box 8097, Emeryville, CA 94662-8097, US,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200441157 A2-A3 20040521 (WO 0441157)
Application: WO 2003US29167 20030915 (PCT/WO US03029167)
Priority Application: US 2002410839 20020913

Parent Application/Grant:
Related by Continuation to: US 2002410839 20020913 (CIP)
Designated States:
(Protection type is "patent" unless otherwise stated - for applications prior to 2004)
AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 11057

English Abstract
This application relates to improved Group B Streptococcus ("GBS") saccharide-based vaccines comprising combinations of GBS polysaccharides with polypeptide antigens, and vice versa, such that the polypeptide and the saccharide each contribute to the immunological response in a recipient. The combination is particularly advantageous where the saccharide and polypeptide are from different GBS serotypes. The combined antigens may be present as a simple combination where separate saccharide and polypeptide antigens are administered together, or they may be present as a conjugated combination, where the saccharide and polypeptide antigens are covalently linked to each other. Preferably, the immunogenic compositions of the invention comprise a GBS saccharide antigen and at least two GBS polypeptide antigens, wherein said GBS saccharide antigen comprises a saccharide selected form GBS serotype Ia, Ib, and III, and wherein said GBS polypeptide antigens comprise a combination of at least two polypeptide or fragments thereof selected from the antigen group consisting of GBS 80, GBS 91, GBS 104, GBS 147, GBS 173, GBS 276, GBS 305, GBS 313, GBS 322, GBS 328, GBS 330, GBS 338, GBS 358, GBS 361, GBS 404, GBS 656, GBS 690, and GBS 691.

French Abstract
L'invention concerne des vaccins ameliores a base de saccharide contre les streptocoques du groupe B (GBS) comprenant des polysaccharides combines avec des antigenes polypeptidiques, et vice versa, de sorte que le polypeptide et le saccharide contribuent chacun a la reaction immunologique chez un patient. Cette combinaison est particulierement avantageuse lorsque le saccharide et le polypeptide proviennent de serotypes GBS differents. Les antigenes combines peuvent etre presents sous la forme d'une simple combinaison, les antigenes saccharidiques et polypeptidiques separes etant administres ensemble, ou sous la forme d'une combinaison conjuguee, les antigenes saccharidiques et polypeptidiques etant lies par covalence les uns aux autres. De preference, les compositions immunogenes de l'invention comprennent un antigene saccharidique GBS et au moins deux antigenes polypeptidiques GBS, ledit antigene saccharidique GBS renfermant un saccharide choisi parmi le serotype GBS Ia, Ib et III, lesdits antigenes polypeptidiques GBS renfermant une combinaison d'au moins deux polypeptides ou fragments correspondants choisis dans le groupe d'antigenes constitue par GBS 80, GBS 91, GBS 104, GBS 147, GBS 173, GBS 276, GBS 305, GBS 313, GBS 322, GBS 328, GBS 330, GBS 338, GBS 358, GBS 361, GBS 404, GBS 656, GBS 690, et GBS 691.

2/3,AB/19 (Item 15 from file: 349)
01112581

POLYPEPTIDE-VACCINES FOR BROAD PROTECTION AGAINST HYPERVIRULENT MENINGOCOCCAL LINEAGES
VACCINS POLYPEPTIDIQUES OFFRANT UNE LARGE PROTECTION CONTRE DES LIGNEES DE MENINGOCOQUES HYPERVIRULENTES

Patent Applicant/Assignee:
CHIRON SRL, Via Fiorentina 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
PIZZA Mariagrazia, Chiron SRL, Via Fiorentina 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (Designated only for: US)
Legal Representative:
MARSHALL Cameron John (et al) (agent), Carpmaels & Ransford, 43-45 Bloomsbury Square, London WC1A 2RA, GB,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200432958 A1 20040422 (WO 0432958)
Application: WO 2003IB4848 20031002 (PCT/WO IB03004848)
Priority Application: GB 200223741 20021011; GB 20035831 20030313 ; GB 20039115 20030422
Designated States:
(Protection type is "patent" unless otherwise stated - for applications prior to 2004)
AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 17203

English Abstract
A small number of defined antigens can provide broad protection against meningococcal infection, and the invention provides a composition which, after administration to a subject, is able to induce an antibody response in that subject, wherein the antibody response is bactericidal against two or three of hypervirulent lineages A4, ET 5 and lineage 3 of N.meningitidis serogroup B. Rather than consisting of a single antigen, the composition comprises a mixture of 10 or fewer purified antigens, and should not include complex or undefined mixtures of antigens such as outer membrane vesicles. Five protein antigens are used in particular: (1) a 'NadA' protein; (2) a '741' protein; (3) a '936' protein; (4) a '953' protein; and (5) a '287' protein.

French Abstract
Un petit nombre d'antigenes definis permettent d'offrir une large protection contre l'infection a meningocoque. L'invention concerne une composition qui, apres avoir ete administree a un sujet, est capable d'induire une reponse des anticorps chez ce sujet, la reponse des anticorps etant bactericide contre deux ou trois des lignees hypervirulentes A4, ET5 et contre la lignee 3 de N.meningitidis du serogroupe B. La composition, plutot que de renfermer un seul antigene, comprend un melange de 10

antigenes purifies au maximum, et ne devrait pas comprendre de melanges complexes ou non definis d'antigenes tels que les vesicules membranaires externes. Dans l'invention, cinq antigenes proteiniques sont utilises en particulier: (1) une proteine "NadA"; (2) une proteine "741"; (3) une proteine "936"; (4) une proteine "953"; et (5) une proteine "287".

2/3,AB/20 (Item 16 from file: 349)
01097829

CONSERVED AND SPECIFIC STREPTOCOCCAL GENOMES
GENOMES DE STREPTOCOQUES CONSERVES OU SPECIFIQUES

Patent Applicant/Assignee:
CHIRON CORPORATION, 4560 Horton Street, Emeryville, CA 94608-2916, US, US (Residence), US (Nationality), (For all designated states except: US)
THE INSTITUTE FOR GENOMIC RESEARCH, 9712 Medical Center Drive, Rockville, MD 20850, US, US (Residence), US (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
TETTELIN Herve, c/o The Institute for Genomic Research, 9712 Medical Center Drive, Rockville, MD 20850, US, US (Residence), BE (Nationality), (Designated only for: US)
MASIGNANI Vega, c/o Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608, US, IT (Residence), IT (Nationality), (Designated only for: US)
Legal Representative:
HALE Rebecca M (et al) (agent), Chiron Corporation, Intellectual Property R338, P.O. Box 8097, Emeryville, CA 94662-8097, US,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200418646 A2 20040304 (WO 0418646)
Application: WO 2003US26827 20030826 (PCT/WO US03026827)
Priority Application: US 2002406237 20020826; US 2002406676 20020827; US 2002406757 20020828
Parent Application/Grant:
Related by Continuation to: US 2002406237 20020826 (CIP); US 2002406676 20020827 (CIP); US 2002406757 20020828 (CIP)
Designated States:
(Protection type is "patent" unless otherwise stated - for applications prior to 2004)
AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 297825

English Abstract

The invention relates to polynucleotides which are conserved or specific to one or more species of Streptococcus, Streptococcus species serotypes, and/or serotype isolates. In particular, the invention relates to polynucleotides from Streptococcus which are conserved or specific to one or more of the species of S. pneumoniae ("pneumococcus" or "S. pn."), S. pyogenes ("group A streptococcus" or "GAS"), and S. agalactiae ("group B streptococcus" or "GBS"). The invention further relates to polynucleotides which are conserved or specific to one or more Streptococcal species serotypes, such as GBS serotypes Ia, Ib, II, III, IV, V, VI, VII, and VIII. The invention still further relates to polynucleotides which are conserved or specific to one or more clinical isolates of a Streptococcus species.

French Abstract

Cette invention concerne des polynucleotides conserves ou specifiques d'une ou de plusieurs especes de streptocoques, de serotypes d'especes de streptocoques et/ou d'isolats de serotypes. L'invention concerne en particulier des polynucleotides de streptocoques qui sont conservee ou specifiques d'une ou de plusieurs especes de S. pneumoniae ("pneumococcus" ou "S. pn."), S. pyogenes ("streptocoques du groupe A" ou "GAS"), et S. agalactiae ("streptocoques du groupe B " ou "GBS"). L'invention concerne egalement des polynucleotides qui sont conserves ou specifiques d'un ou de plusieurs serotypes d'especes streptococciques, tels que les serotypes GBS Ia, Ib, II, III, IV, V, VI, VII, et VIII. L'invention concerne en outre des polynucleotides qui sont conserves ou specifiques d'un ou de plusieurs isolats cliniques d'une espece de streptocoque.

2/3,AB/21 (Item 17 from file: 349)
01065645

MUCOSAL COMBINATION VACCINES FOR BACTERIAL MENINGITIS
VACCINS COMBINES DESTINES A ETRE ADMINISTRES AUX MUQUEUSES POUR L'IMMUNISATION CONTRE LA MENINGITE BACTERIENNE

Patent Applicant/Assignee:
CHIRON SRL, Via Fiorentina 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
O'HAGAN Derek Thomas, Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608-2916, US, US (Residence), US (Nationality), (Designated only for: US)
Legal Representative:
MARSHALL Cameron John (agent), Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA, GB,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200394960 A2-A3 20031120 (WO 0394960)
Application: WO 2003IB2648 20030514 (PCT/WO IB03002648)
Priority Application: US 2002380675 20020514
Designated States:
(Protection type is "patent" unless otherwise stated - for applications prior to 2004)
AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 5947

English Abstract
A composition for mucosal delivery, comprising two or more of the following: (a) an antigen which induces an immune response against Haemophilus influenzae; (b) an antigen which induces an immune response against Neisseria meningitidis; and (c) an antigen which induces an immune response against Streptococcus pneumoniae. The combination allows a single dose for immunising against three separate causes of a common disease, namely bacterial meningitis.

French Abstract
L'invention concerne une composition destinee a etre administree aux muqueuses, comprenant deux ou plus de deux elements, qui sont: (a) un antigene induisant une reponse immunitaire contre Haemophilus influenzae; (b) un antigene induisant une reponse immunitaire contre Neisseria meningitidis; et (c) un antigene induisant une reponse immunitaire contre Streptococcus pneumoniae. Cette combinaison donne une forme unique pour l'immunisation contre trois vecteurs distincts d'une maladie commune, a savoir la meningite bacterienne.

2/3,AB/22 (Item 18 from file: 349)
01065644
MUCOSAL VACCINES WITH CHITOSAN ADJUVANT AND MENINGOCOCCAL ANTIGENS
VACCINS MUQUEUX AVEC ADJUVANT DE CHITOSANE ET/OU ANTIGENES MENINGOCOCCIQUES

Patent Applicant/Assignee:
UNIVERSITEIT LEIDEN, Leiden/Amsterdam Center for Drug Research, Einsteinweg 55, NL-2333 CC Leiden, NL, NL (Residence), NL (Nationality), (For all designated states except: US)
CHIRON SRL, Via Fiorentina 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
DEL GIUDICE Giuseppe, Chiron SpA, Via Florentina, 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (Designated only for: US)
BAUDNER Barbara, Chiron SpA, Via Florentina, 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (Designated only for: US)
Legal Representative:
MARSHALL Cameron John (et al) (agent), Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA, GB,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200394834 A2-A3 20031120 (WO 0394834)
Application: WO 2003IB2382 20030514 (PCT/WO IB03002382)
Priority Application: US 2002380675 20020514; GB 20032218 20030130

Designated States:
(Protection type is "patent" unless otherwise stated - for applications prior to 2004)
AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 9472

English Abstract
The invention provides immunogenic compositions comprising (a) a capsular saccharide antigen from serogroup C of N.meningitidis, and (b) a chitosan adjuvant. The composition preferably comprises (c) one or more further antigens and/or (d) one or more further adjuvants. The compositions are particularly suitable for mucosal delivery, including intranasal delivery. The invention also provides immunogenic compositions for mucosal delivery comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of N.meningitidis. It is preferred that the capsular saccharides in the compositions of the invention are conjugated to carrier protein(s) and/or are oligosaccharides. Conjugated oligosaccharide antigens are particularly preferred.

French Abstract
La presente invention concerne des compositions immunogenes comprenant (a) un antigene saccharide capsulaire du serogroupe C de N.meningitidis, et (b) un adjuvant de chitosane. Cette composition comprend, de preference, (c) un ou plusieurs antigenes et/ou (d) un au plusieurs autres adjuvants. Ces compositions conviennent particulierement pour un apport muqueux, notamment un apport intranasal. Cette invention concerne aussi des compositions immunogenes destinees a un apport muqueux comprenant des saccharides capsulaires d'au moins deux des serogroupes A, C, W135 et Y de N.meningitidis. Il est preferable que les saccharides capsulaires presents dans les compositions de cette invention soient conjugues avec une ou des proteines porteuses et/ou qu'elles soient des oligosaccharides. Des antigenes oligosaccharides conjugues sont particulierement preferes.

2/3,AB/23 (Item 19 from file: 349)
01017951
ADJUVANTED ANTIGENIC MENINGOCOCCAL COMPOSITIONS
COMPOSITIONS MENINGOCOCCIQUES ANTIGENIQUES A ADJUVANTS

Patent Applicant/Assignee:
CHIRON SRL, Via Florentina, 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
PIZZA Mariagrazia, Chiron S.p.A., Via Fiorentina, 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (Designated only for: US)

GIULIANI Marzia Monica, Chiron SpA, Via Fiorentina, 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (Designated only for: US)
Legal Representative:
MARSHALL Cameron John (et al) (agent), Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA, GB,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200347619 A2-A3 20030612 (WO 0347619)
Application: WO 2002IB5662 20021204 (PCT/WO IB0205662)
Priority Application: GB 200129007 20011204
Designated States:
(Protection type is "patent" unless otherwise stated - for applications prior to 2004)
AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
(EP) AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR
(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 7437

English Abstract
A composition comprising a Neisserial antigen and a detoxified ADP-ribosylating toxin. These compositions have been found to be useful for mucosal immunisation, particularly nasal immunisation against Neisseria meningitidis.

French Abstract
L'invention concerne une composition contenant un antigene Neisserial et une toxine ADP-ribosylantes detoxiquee. Ces compositions se sont revelees utiles a l'immunisation des muqueuses, notamment l'immunisation nasale contre Neisseria meningitidis.

2/3,AB/24 (Item 20 from file: 349)
00848084
ISOLATION AND CHARACTERIZATION OF THE CSA OPERON (ETEC-CS4 PILI) AND METHODS OF USING SAME
ISOLATION ET CARACTERISATION DE L'OPERON CSA (ETEC-CS4 PILI) ET PROCEDE D'UTILISATION CORRESPONDANT

Patent Applicant/Assignee:
UNIVERSITY OF MARYLAND BALTIMORE, 520 West Lombard Street, Baltimore, MD 21201-1627, US, US (Residence), US (Nationality)
Inventor(s):
ALTBOUM Zeev, Dresner Street 11, 69497 Ramat Aviv, IL,
LEVINE Myron M, 5209 Windmill Lane, Columbia, MD 21044, US,
BARRY Eileen M, 6885 Old Waterloo Road, Elkridge, MD 21075, US,

Legal Representative:
MULLEN James J (agent), Knobbe, Martens, Olson & Bear, LLP, 16th Floor, 620 Newport Center Drive, Newport Beach, CA 92660, US,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200181582 A2-A3 20011101 (WO 0181582)
Application: WO 2001US12914 20010420 (PCT/WO US0112914)
Priority Application: US 2000198686 20000420
Designated States:
(Protection type is "patent" unless otherwise stated - for applications prior to 2004)
AE AG AL AM AT AT (utility model) AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ (utility model) DE DE (utility model) DK DK (utility model) DM DZ EE EE (utility model) ES FI FI (utility model) GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK (utility model) SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW
(EA) AM AZ BY KG KZ MD RU TJ TM
Publication Language: English
Filing Language: English
Fulltext Word Count: 20843

English Abstract
Compositions comprising products of the csa operon, an isolated nucleic acid encoding the csa operon or functional fragments thereof, purified polypeptide products of the csa operon or functional fragments thereof, methods of eliciting an immune response to these products, and methods of producing products of the csa operon are disclosed herein.

French Abstract
L'invention porte sur des compositions comprenant des produits de l'operon csa, sur un acide nucleique isole codant l'operon csa ou sur ses fragments fonctionnels, sur des produits polypeptidiques purifies de l'operon csa ou sur ses fragments fonctionnels, sur des procedes visant a eliciter une reponse immune a ces produits, et sur des procedes de production de produits de l'operon csa.

2/3,AB/25 (Item 21 from file: 349)
00789771
MUCOSAL DTPa VACCINES
VACCINS DTPA DES MUQUEUSES VACCINES

Patent Applicant/Assignee:
CHIRON S P A, Via Fiorentina, 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (For all designated states except: US)
Patent Applicant/Inventor:
RAPPUOLI Rino, Chiron S.p.A., Via Fiorentina, 1, I-53100 Siena, IT, IT (Residence), IT (Nationality), (Designated only for: US)
PIZZA Mariagrazia, Chiron S.p.A., Via Fiorentina, 1, I-53100 Siena, IT, IT (Residence), IT

(Nationality), (Designated only for: US)
Legal Representative:
HALLYBONE Huw George (et al) (agent), Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA, GB,
Patent and Priority Information (Country, Number, Date):
Patent: WO 200122993 A2-A3 20010405 (WO 0122993)
Application: WO 2000IB1440 20000928 (PCT/WO IB0001440)
Priority Application: GB 9923060 19990929
Designated States:
(Protection type is "patent" unless otherwise stated - for applications prior to 2004)
CA JP US
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
Publication Language: English
Filing Language: English
Fulltext Word Count: 4684

English Abstract
Mucosal DTPa vaccines, especially intranasal vaccines, comprising (a) a diphtheria antigen, a tetanus antigen and an acellular pertussis antigen, and (b) a detoxified mutant of cholera toxin (CT) or E.coli heat labile toxin (LT). Component (b) acts as a mucosal adjuvant. The acellular pertussis antigen preferably comprises pertussis holotoxin (PT) and filamentous haemagglutinin (FHA) and, optionally, pertactin. The mucosally-delivered combined DTPa formulation is capable of generating a level of protection against B.pertussis infection equivalent to that observed by alum-adjuvanted parenteral administration.

French Abstract
Cette invention concerne des vaccins DTPa administres par les muqueuses, en particulier des vaccins intranasaux, comprenant (a) un antigene de la diphterie, un antigene du tetanos et un antigene acellulaire de la coqueluche acellulaire, et (b) un mutant detoxifie de la toxine du cholera (CT) ou une toxine thermolabile deE.coli (LT). Le composant (b) agit comme un adjuvant pour les muqueuses. L'antigene acellulaire de la coqueluche comprend de preference une holotoxine de la coqueluche, une hemo-agglutinine filamenteuse et eventuellement de la pertactine. La formulation DTPa combinee administree dans les muqueuse assure un niveau de protection contre l'infection par B.pertussis equivalent a celui d'une administration parenterale avec adjuvant alun.

2/3,AB/26 (Item 22 from file: 349)
00568674
PLASMID MAINTENANCE SYSTEM FOR ANTIGEN DELIVERY
SYSTEME DE STABILISATION DE PLASMIDES PERMETTANT D'ADMINISTRER DES ANTIGENES

Patent Applicant/Assignee:
UNIVERSITY OF MARYLAND BALTIMORE,
GALEN James E,
Inventor(s):
GALEN James E,
Patent and Priority Information (Country, Number, Date):

Patent: WO 200032047 A1 20000608 (WO 0032047)
Application: WO 99US28499 19991202 (PCT/WO US9928499)
Priority Application: US 98204117 19981202; US 99158738 19991012
Designated States:
(Protection type is "patent" unless otherwise stated - for applications prior to 2004)
AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
Publication Language: English
Fulltext Word Count: 34866

English Abstract
The present invention relates generally to a Plasmid Maintenance System for the stabilization of expression plasmids encoding foreign antigens, and methods for making and using the Plasmid Maintenance System. The invention optimizes the maintenance of expression plasmids at two independent levels by: (1) removing sole dependence on balanced lethal maintenance functions; and (2) incorporating at least one plasmid partition function to prevent random segregation of expression plasmids, thereby enhancing their inheritance and stability. The Plasmid Maintenance System may be employed within a plasmid which has been recombinantly engineered to express a variety of expression products.

French Abstract
L'invention concerne en general un systeme de stabilisation de plasmides, permettant de stabiliser des plasmides d'expression qui codent pour des antigenes etrangers, et des procedes de production et d'utilisation dudit systeme de stabilisation de plasmides. L'invention optimise la stabilisation de plasmides a deux niveaux independants: 1) par elimination d'une dependance exclusive sur des fonctions de stabilisation letale equilibrees; et 2) par incorporation d'au moins une fonction de partition de plasmide, afin d'empecher la segregation aleatoire des plasmides d'expression, ce qui ameliore leur heredite et leur stabilite. Le systeme de stabilisation de plasmides peut etre utilise dans un plasmide qui a ete mis au point par genie genetique par recombinaison, afin d'exprimer une variete de produits d'expression.

2/3,AB/27 (Item 1 from file: 440)
10287272
PUBLICATION: Journal: VACCINE , 1999

ISSN: 0264-410X

2/3,AB/28 (Item 2 from file: 440)
08668934 **Number of References:** 0
Title: Novel molecular biology approaches to acellular vaccines

Author: Rappuoli R (REPRINT); Pizza M ; ElGewely MR
Corporate Source: IRIS,CHIRON BIOCINE IMMUNOBIOL RES INST SIENA/SIENA//ITALY/ (REPRINT)
Publication Type: BOOK IN SERIES
Publication: BIOTECHNOLOGY ANNUAL REVIEW, VOL 2 , 1996 , V 2 , P 391-408
Genuine Article#: BJ21K
Book Series Title: BIOTECHNOLOGY ANNUAL REVIEW
Publisher: ELSEVIER SCIENCE PUBL B V , SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
ISBN: 0-444-82444-8
Language: English **Document Type:** ARTICLE

2/3,AB/29 (Item 1 from file: 654)

6466335
Derwent Accession: 2004-034580
UTILITY
Mucosal vaccines with chitosan adjuvant and meningococcal antigens
Inventor: Guidice, Giuseppe Del, Siena, IT
Baudner, Barbara, Marburg, DE
Assignee: Unassigned
Correspondence Address: Chiron Corporation;Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20060051378	A1	20060309	US 2003514207	20030514
PCT filing				WO 2003IB2382	20030514
Provisional				US 60-380675	20020514
Priority				GB 20032218	20030130

Fulltext Word Count: 10082
Abstract:
[00000] The invention provides immunogenic compositions comprising (a) a capsular saccharide antigen from serogroup C of N. meningitidis, and (b) a chitosan adjuvant. The composition preferably comprises (c) one or more further antigens and/or (d) one or more further adjuvants. The compositions are particularly suitable for mucosal delivery, including intranasal delivery. The invention also provides immunogenic compositions for mucosal delivery comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of N. meningitidis. It is preferred that the capsular saccharides in the compositions of the invention are conjugated to carrier protein(s) and/or are oligosaccharides. Conjugated oligosaccharide antigens are particularly preferred.
(Chemical formulae 1. See patent image)

2/3,AB/30 (Item 2 from file: 654)

6437718
Derwent Accession: 2005-075653
UTILITY
Immunogenic compositions for Chlamydia trachomatis

Inventor: Grandi, Guido, Milano, IT
Ratti, Guilio, Siena, IT
Bonci, Alessandra, Siena, IT
Finco, Oretta, Castelnuovo Berardenga, IT
Assignee: Chiron Corporation, (02), Emeryville, CA, US
Correspondence Address: Chiron Corporation;Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20060034871	A1	20060216	US 200418868	20041222
CIP	PENDING			WO 2004US20491	20040625
Provisional				US 60-497649	20030825
Provisional				US 60-576375	20040601
Priority				GB 200315020	20030626
				GB 20042236	20040202

Fulltext Word Count: 47861
Abstract:
[00000] The invention relates to immunogenic compositions comprising combinations of Chlamydia trachomatis antigens and their use in vaccines. The composition may comprise at least two components, one component of which comprises Chlamydia trachomatis antigens for eliciting a Chlamydia trachomatis specific TH1 immune response and another component of which comprises antigens for eliciting a Chlamydia trachomatis specific TH2 immune response. The invention further relates to an immunogenic composition comprising a Chlamydia trachomatis Type III secretion system (TTSS) regulatory protein and a Chlamydia trachomatis Type III secretion system (TTSS) secreted protein or a fragment thereof. The invention further relates to the use of combinations of adjuvants for use with antigens associated with a sexually transmissible disease, such as Chlamydia trachomatis antigens. Preferred adjuvant combinations include mineral salts, such as aluminium salts and oligonucleotides comprising a CpG motif. The invention further provides a combination of Chlamydia trachomatis antigens comprising a Chlamydia trachomatis antigen that is conserved over at least two serovars.

2/3,AB/31 (Item 3 from file: 654)

6428974
Derwent Accession: 2000-412091
UTILITY
Plasmid maintenance system for antigen delivery
Inventor: Galen, James E., Owings Mills, MD, US
Assignee: UNIVERSITY OF MARYLAND, BALTIMORE, (02)
Correspondence Address: SUGHRUE MION, PLLC, 2100 PENNSYLVANIA AVENUE, N.W., SUITE 800, WASHINGTON, DC, 20037, US

	Publication			Application	Filing

	Number	Kind	Date	Number	Date
Main Patent	US 20060030048	A1	20060209	US 2005229073	20050919
Division	US 6703233			US 99453313	19991202
Continuation	US 6977176			US 2004750976	20040105
CIP	US 6413768			US 98204117	19981202
Provisional				US 60-158738	19991012

Fulltext Word Count: 30659

Abstract:

[00000] The present invention relates generally to a Plasmid Maintenance System for the stabilization of expression plasmids encoding foreign antigens, and methods for making and using the Plasmid Maintenance System. The invention optimizes the maintenance of expression plasmids at two independent levels by: (1) removing sole dependence on balanced lethal maintenance functions; and (2) incorporating at least one plasmid partition function to prevent random segregation of expression plasmids, thereby enhancing their inheritance and stability. The Plasmid Maintenance System may be employed within a plasmid which has been recombinantly engineered to express a variety of expression products.

2/3,AB/32 (Item 4 from file: 654)

6428973

Derwent Accession: 2000-412091

UTILITY

Plasmid maintenance system for antigen delivery

Inventor: Galen, James E., Owings Mills, MD, US

Assignee: UNIVERSITY OF MARYLAND, BALTIMORE, (02)

Correspondence Address: SUGHRUE MION, PLLC, 2100 PENNSYLVANIA AVENUE, N.W., SUITE 800, WASHINGTON, DC, 20037, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20060030047	A1	20060209	US 2005229069	20050919
Division	US 6703233			US 99453313	19991202
Continuation	US 6977176			US 2004750976	20040105
CIP	US 6413768			US 98204117	19981202
Provisional				US 60-158738	19991012

Fulltext Word Count: 30488

Abstract:

[00000] The present invention relates generally to a Plasmid Maintenance System for the stabilization of expression plasmids encoding foreign antigens, and methods for making and using the Plasmid Maintenance System. The invention optimizes the maintenance of expression plasmids at two independent levels by: (1) removing sole dependence on balanced lethal maintenance functions; and (2) incorporating at least one plasmid partition function to prevent random segregation of expression plasmids, thereby enhancing their inheritance and stability. The Plasmid Maintenance System may be employed within a plasmid which has been recombinantly engineered to express a variety of expression products.

2/3,AB/33 (Item 5 from file: 654)

6428543
Derwent Accession: 2000-412091
UTILITY
Plasmid maintenance system for antigen delivery
Inventor: Galen, James E., Owings Mills, MD, US
Assignee: UNIVERSITY OF MARYLAND, BALTIMORE, (02)
Correspondence Address: SUGHRUE MION, PLLC, 2100 PENNSYLVANIA AVENUE, N.W., SUITE 800, WASHINGTON, DC, 20037, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20060029616	A1	20060209	US 2005229306	20050919
Division	US 6703233			US 99453313	19991202
Continuation	US 6977176			US 2004750976	20040105
CIP	US 6413768			US 98204117	19981202
Provisional				US 60-158738	19991012

Fulltext Word Count: 30356
Abstract:
[00000] The present invention relates generally to a Plasmid Maintenance System for the stabilization of expression plasmids encoding foreign antigens, and methods for making and using the Plasmid Maintenance System. The invention optimizes the maintenance of expression plasmids at two independent levels by: (1) removing sole dependence on balanced lethal maintenance functions; and (2) incorporating at least one plasmid partition function to prevent random segregation of expression plasmids, thereby enhancing their inheritance and stability. The Plasmid Maintenance System may be employed within a plasmid which has been recombinantly engineered to express a variety of expression products.

2/3,AB/34 (Item 6 from file: 654)

6395455
Derwent Accession: 2003-505258
UTILITY
Adjuvanted antigenic meningococcal compositions
Inventor: Pizza, Mariagrazia, Siena, IT
Guiliani, Marzia Monica, Siena, IT
Assignee: Unassigned
Correspondence Address: Chiron Corporation;Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20060008476	A1	20060112	US 2002497709	20021204
PCT filing				WO 2002IB5662	20021204
Priority				GB 200129007	20011204

Fulltext Word Count: 7721
Abstract:

[00000] A composition comprising a Neisserial antigen and a detoxified ADP-ribosylating toxin. These compositions have been found to be useful for mucosal immunisation, particularly nasal immunisation against Neisseria meningitidis.

2/3,AB/35 (Item 7 from file: 654)

6366682
Derwent Accession: 2000-412091
UTILITY
Plasmid maintenance system for antigen delivery
Inventor: Galen, James E., Owings Mills, MD, US
Assignee: University of Maryland, (02), Baltimore, MD, US
Examiner: Guzo, David
Legal Representative: Sughrue Mion, PLLC

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 6977176	B2	20051220	US 2004750976	20040105
Related Publ	US 20050003539	A1	20050106		
Division	US 6703233	A		US 99453313	19991202
CIP	US 6413768	A		US 98204117	19981202
Provisional				US 60-158738	19991012

US Term Extension: 100 days
Fulltext Word Count: 30416
Abstract:
[00000] The present invention relates generally to a Plasmid Maintenance System for the stabilization of expression plasmids encoding foreign antigens, and methods for making and using the Plasmid Maintenance System. The invention optimizes the maintenance of expression plasmids at two independent levels by: (1) removing sole dependence on balanced lethal maintenance functions; and (2) incorporating at least one plasmid partition function to prevent random segregation of expression plasmids, thereby enhancing their inheritance and stability. The Plasmid Maintenance System may be employed within a plasmid which has been recombinantly engineered to express a variety of expression products.

2/3,AB/36 (Item 8 from file: 654)

6341875
Derwent Accession: 2000-412091
UTILITY
Plasmid maintenance system for antigen delivery
Inventor: Galen, James E., Owings Mills, MD, US
Assignee: University of Maryland, Baltimore, (02), Baltimore, MD, US
Examiner: Guzo, David

Legal Representative: Sughrue Mion, PLLC

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 6969513	B2	20051129	US 2004750965	20040105
Related Publ	US 20040161420	A1	20040819		
Division	US 6703233	A		US 99453313	19991202
CIP	US 6413768	A		US 98204117	19981202
Provisional				US 60-158738	19991012

US Term Extension: 79 days
Fulltext Word Count: 30582
Abstract:

[00000] The present invention relates generally to a Plasmid Maintenance System for the stabilization of expression plasmids encoding foreign antigens, and methods for making and using the Plasmid Maintenance System. The invention optimizes the maintenance of expression plasmids at two dependent levels by: (1) removing sole dependence on balanced lethal maintenance functions; and (2) incorporating at least one plasmid partition function to present random segregation of expression plasmids, thereby enhancing their inheritance and stability. The Plasmid Maintenance System may be employed within a plasmid which has been recombinantly engineered to express a variety of expression products.

2/3,AB/37 (Item 9 from file: 654)

6263646
Derwent Accession: 1998-437145
UTILITY

Microparticles with adsorbent surfaces, methods of making same, and uses thereof

Inventor: O' Hagan, Derek, Berkeley, CA, US
Singh, Manmohan, Hercules, CA, US
Ott, Gary, Oakland, CA, US
Barackman, John, Dublin, CA, US
Kazzaz, Jina, San Rafael, CA, US
Assignee: Unassigned
Correspondence Address: Helen Lee;Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20050208143	A1	20050922	US 2005113861	20050425
Continuation	US 6884435			US 2000581772	20000615
CIP	ABANDONED			US 99285855	19990402
CIP	ABANDONED			US 98124533	19980729
CIP	ABANDONED			US 9815652	19980129
Provisional				US 60-36316	19970130
Provisional				US 60-69749	19971216

Fulltext Word Count: 14652
Abstract:

[00000] Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly([small alpha, Greek]-hydroxy acid), a

polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surface of the microparticles efficiently adsorb biologically active macromolecules, such as DNA, polypeptides, antigens, and adjuvants.

2/3,AB/38 (Item 10 from file: 654)

6235965
Derwent Accession: 1998-437145
UTILITY
Microparticles with adsorbent surfaces, methods of making same, and uses thereof
Inventor: O' Hagan, Derek, Berkeley, CA, US
Singh, Manmohan, Hercules, CA, US
Ott, Gary, Oakland, CA, US
Barackman, John, Dublin, CA, US
Kazzaz, Jina, San Rafael, CA, US
Assignee: Unassigned
Correspondence Address: Helen Lee;Chiron Corporation, Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20050191319	A1	20050901	US 2005113767	20050425
Continuation	US 6884435			US 2000581772	20000615
CIP	ABANDONED			US 99285855	19990402
CIP	ABANDONED			US 98124533	19980729
CIP	ABANDONED			US 9815652	19980129
Provisional				US 60-36316	19970130
Provisional				US 60-69749	19971216

Fulltext Word Count: 14150
Abstract:
[00000] Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly([small alpha, Greek]-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surface of the microparticles efficiently adsorb biologically active macromolecules, such as DNA, polypeptides, antigens, and adjuvants.

2/3,AB/39 (Item 11 from file: 654)

6122903
Derwent Accession: 2005-223088

UTILITY
Immunogenic compositions containing microparticles comprising adsorbed toxoid and polysaccharide-containing antigens
Inventor: O'Hagan, Derek, Berkeley, CA, US
Assignee: Unassigned
Correspondence Address: Chiron Corporation;Intellectual Property - R440, P.O. Box 8097, Emeryville, CA, 94662-8097, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20050118275	A1	20050602	US 2004858858	20040602
Provisional				US 60-475010	20030602
Provisional				US 60-513074	20031021

Fulltext Word Count: 17306
Abstract:

[00000] Immunogenic compositions comprising microparticles with adsorbed toxoid antigen and/or polysaccharide-containing antigen are disclosed. The immunogenic microparticle compositions comprise (a) polymer microparticles comprising a biodegradable polymer; (b) an antigen adsorbed to the microparticles selected from (i) a toxoid antigen, such as a tetanus toxoid, a diphtheria toxoid, or a combination thereof, and/or (ii) a polysaccharide containing antigen, such as a Hib polysaccharide antigen, a Hib conjugate antigen comprising polysaccharide and polypeptide regions, a meningococcal polysaccharide antigen, a meningococcal conjugate antigen comprising polysaccharide and polypeptide regions, a pneumococcal polysaccharide antigen, and a pneumococcal conjugate antigen comprising polysaccharide and polypeptide regions or a combination thereof; and (c) a pharmaceutically acceptable excipient. The biodegradable polymer can be, for example, a polymer selected from a poly([small alpha, Greek]-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and a polycyanoacrylate. Also disclosed are methods of immunization against infection by a pathogenic organisms and methods stimulating immune responses, which comprise administering such compositions to host animals. Methods of producing such microparticle compositions are also disclosed which comprise forming a water-in-oil-in-water emulsion that contains water, organic solvent and biodegradable polymer, followed by removal of the organic solvent from the emulsion to form microparticles, after which toxoid and/or polysaccharide containing antigens are adsorbed on the microparticles.

2/3,AB/40 (Item 12 from file: 654)

0005941118
Derwent Accession: 2000-412091
Plasmid maintenance system for antigen delivery
Inventor: Galen, James, INV
Assignee: UNIVERSITY OF MARYLAND, BALTIMORE 02)
Correspondence Address: SUGHRUE MION, PLLC, 2100 PENNSYLVANIA AVENUE, N.W. SUITE 800, WASHINGTON, DC, 20037, US

	Publication Number	Kind	Date	Application Number	Filing Date

Main Patent	US 20050003539	A1	20050106	US 2004750976	20040105
Division	US 6703233			US 99453313	19991202
CIP	US 6413768			US 98204117	19981202
Provisional				US 60-158738	19991012

Fulltext Word Count: 32207

Abstract:

The present invention relates generally to a Plasmid Maintenance System for the stabilization of expression plasmids encoding foreign antigens, and methods for making and using the Plasmid Maintenance System. The invention optimizes the maintenance of expression plasmids at two independent levels by: (1) removing sole dependence on balanced lethal maintenance functions; and (2) incorporating at least one plasmid partition function to prevent random segregation of expression plasmids, thereby enhancing their inheritance and stability. The Plasmid Maintenance System may be employed within a plasmid which has been recombinantly engineered to express a variety of expression products.

2/3,AB/41 (Item 13 from file: 654)

0005763806

Derwent Accession: 2000-412091

Plasmid maintenance system for antigen delivery

Inventor: Galen, James, INV

Assignee: UNIVERSITY OF MARYLAND, BALTIMORE 02)

Correspondence Address: SUGHRUE MION, PLLC, 2100 PENNSYLVANIA AVENUE, N.W. SUITE 800, WASHINGTON, DC, 20037, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20040161420	A1	20040819	US 2004750965	20040105
Division	US 6703233			US 99453313	19991202
CIP	US 6413768			US 98204117	19981202
Provisional				US 60-158738	19991012

Fulltext Word Count: 38189

Abstract:

The present invention relates generally to a Plasmid Maintenance System for the stabilization of expression plasmids encoding foreign antigens, and methods for making and using the Plasmid Maintenance System. The invention optimizes the maintenance of expression plasmids at two independent levels by: (1) removing sole dependence on balanced lethal maintenance functions; and (2) incorporating at least one plasmid partition function to prevent random segregation of expression plasmids, thereby enhancing their inheritance and stability. The Plasmid Maintenance System may be employed within a plasmid which has been recombinantly engineered to express a variety of expression products.

2/3,AB/42 (Item 14 from file: 654)

0005125433
Derwent Accession: 2003-352604
Isolation and characterization of the csa operon (ETEC-CS4 pili) and methods of using same
Inventor: Zeev Altboum, INV
Myron Levine, INV
Eileen Barry, INV
Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP, 620 NEWPORT CENTER DRIVE SIXTEENTH FLOOR, NEWPORT BEACH, CA, 92660, US

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 20020176868	A1	20021128	US 2001839894	20010420
Provisional				US 60-198626	20000420

Fulltext Word Count: 22568
Abstract:
Compositions comprising products of the csa operon, an isolated nucleic acid encoding the csa operon or functional fragments thereof, purified polypeptide products of the csa operon or functional fragments thereof, methods of eliciting an immune response to these products, and methods of producing products of the csa operon are disclosed herein.

2/3,AB/43 (Item 15 from file: 654)

4707675
Derwent Accession: 2000-412091
Utility
C/ **Expression plasmids**
; MAINTENANCE SYSTEM; PLASMID HAS RESTRICTED COPY NUMBER ORIGIN OF REPLICATION WITH TRANSCRIPTIONAL TERMINATORS, A SELECTION MARKER, A POST-SEGREGATIONAL KILLING SYSTEM, AND AN INDUCIBLE PROMOTER
Inventor: Galen, James E., Owings Mills, MD
Assignee: University of Maryland 02), Baltimore, MD
Maryland, University of (Code: 52744)
Examiner: Yucel, Remy (Art Unit: 166)
Law Firm: Knobbe, Martens, Olson & Bear LLP

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 6413768	A	20020702	US 98204117	19981202

Fulltext Word Count: 27528
Abstract:
The present invention relates generally to a Plasmid Maintenance System for the stabilization of expression plasmids encoding foreign antigens, and methods for making and using the Plasmid Maintenance System. The invention optimizes the maintenance of expression plasmids at two independent levels by: (1) removing sole dependence on balanced lethal maintenance systems; and (2) incorporating a plasmid partition system to prevent random segregation of expression vector plasmids, thereby enhancing their inheritance and stability. The Plasmid Maintenance System

may be employed within a plasmid which has been recombinantly engineered to express a variety of expression products.